I HAD NO IDEA! how big this meeting is. This is the who's who of HEMA. Not saying Regen is there yet but we might be after this... read on my friends...it is really exciting...
Supposedly going to be able to watch daily updates here: Daily Video Updates
And look at the session right before ours in the same room.
Special Scientific Symposium on RNA Therapeutics in Hematology
Saturday, December 6, 2014, 4:00 p.m. - 5:30 p.m. Moscone Center (West Building, 3007-3009-3011-3020-3022-3024)
Single-stranded RNA therapeutics can bind to their target molecules with high affinity and specificity and therefore hold tremendous promise for applications ranging from receptor antagonism to protein function inhibition to gene regulation. Several RNA-based therapeutic drugs are now entering the clinical pipeline for the treatment of thrombosis, cancer, and viral diseases. This session will address the technology and functional repertoire of RNA therapeutics and highlight examples of emerging applications for hematologic disorders.
Dr. Paloma Giangrande will provide an overview of the RNA technology toolbox, including aptamer selection, optimization, and delivery of therapeutic applications in hematology and oncology.
Dr. Akin Akinc will discuss the development of RNA interference (RNAi) therapeutics for hemophilia and complement-related disorders.
Dr. Kevin Morris will reflect on the regulatory role and therapeutic potential of long non-coding RNAs (lncRNAs), specifically turning gene expression down or up in a long-term stable manner.
Click here to review the session
Chair:
Steven R. Lentz, MD, PhD Department of Internal Medicine, Carver College of Medicine, University of Iowa Iowa City, IA
Speakers:
Paloma H. Giangrande, PhD University of Iowa Iowa City, IA Aptamer-Targeted Oligonucleotide Therapeutics: Technology to Clinic
Akin Akinc, PhD Alnylam Pharmaceuticals Cambridge, MA RNAi Therapeutics for Hemophilia and Complement-Mediated Diseases
Kevin V. Morris, PhD The Scripps Research Institute La Jolla, CA Long Noncoding RNA Therapeutics for HIV and Cancer
Looks like a good warm up for our girl.
OH, and by the way...I found this really exciting...
Our session is the first Poster Session, entitled "Poster Session 1", and it just so happens that "poster sessions" are, and I quote:
"Abstracts selected for oral and poster presentations feature the latest research in the field and are considered the best of the thousands submitted for the 2014 ASH Annual Meeting."
We are one of three poster sessions.....and the viewing before the actual presentation starts at 9:00am that day.
News 
Market Data 
Discover 
AI
